AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22036045 — intervention group
Group type: COMPARATOR
Intervention: Non-ambulatory group
Number of subjects: 130
Study 20680859 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine companions (MCs) chosen by participants for ART adherence support
Number of subjects: 1453
Study 20680859 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews regarding the experience with MCs
Number of subjects: 1453
Study 20680859 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who disclosed their serostatus
Number of subjects: 1453
Study 20680859 — intervention group
Group type: EXPERIMENTAL
Intervention: General experience with MCs
Number of subjects: 1453
Study 18203070 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Daily Dialysis with filtration (EDDf)
Number of subjects: 16
Study 18203070 — intervention group
Group type: COMPARATOR
Intervention: Continuous Veno‐Venous Hemofiltration (CVVH)
Number of subjects: 16
Study 15557391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 IU/day
Number of subjects: 80
Study 15557391 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 80
Study 12468775 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK200775 (dose group 2: 525 mg in 48 hours)
Number of subjects: 61
Study 12468775 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK200775 (dose group 1: 262.5 mg in 48 hours)
Number of subjects: 61
Study 12468775 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK200775 (dose group 3: 105 mg over 6 hours)
Number of subjects: 61
Study 12468775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9812120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 10 mg/day
Number of subjects: 243
Study 9812120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 243
Study 9812120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 7609861 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (up to 100 mg/day)
Number of subjects: 66
Study 7609861 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine (up to 200 mg/day)
Number of subjects: 66
Study 7609861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 2559129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cepharanthin (Ceph.) at a dose of 1 mg/kg
Number of subjects: 45
Study 619829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse intervention to improve medication compliance
Number of subjects: 0
Study 619829 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 0
Study 31730273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Root Ganglion (DRG) stimulation
Number of subjects: 217
Study 31394172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified ART plus auranofin
Number of subjects: 15
Study 31394172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified ART (ART + dolutegravir and maraviroc)
Number of subjects: 15
Study 31394172 — intervention group
Group type: COMPARATOR
Intervention: No intervention (continuation of first-line ART)
Number of subjects: 15
Study 28615434 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 402
Study 28615434 — intervention group
Group type: COMPARATOR
Intervention: Traditional consultation
Number of subjects: 402
Study 25587059 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic atrophy (GA) patients
Number of subjects: 72
Study 25587059 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse-trickling GA subtype
Number of subjects: 72
Study 25587059 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diffuse-trickling GA subtype
Number of subjects: 72
Study 23979097 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental modifications including signs encouraging stair use, music, and art posters in stairwells.
Number of subjects: 6
Study 23979097 — intervention group
Group type: COMPARATOR
Intervention: Control group with no environmental modifications.
Number of subjects: 6
Study 22145383 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive treatment
Number of subjects: 112
Study 22145383 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 112
Study 19502023 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TDS) patch
Number of subjects: 126
Study 19502023 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 126
Study 16838228 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of tolevamer per day
Number of subjects: 289
Study 16838228 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of tolevamer per day
Number of subjects: 289
Study 16838228 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of vancomycin per day
Number of subjects: 289
Study 14755206 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 33
Study 14755206 — intervention group
Group type: COMPARATOR
Intervention: Cold scalpel technique
Number of subjects: 33
Study 11063152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 48
Study 11063152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9205815 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.108 mg per kg of IBW)
Number of subjects: 18
Study 9205815 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (0.99 mg per kg of IBW)
Number of subjects: 18
Study 9205815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (0.073 mg per kg of IBW)
Number of subjects: 18
Study 9205815 — intervention group
Group type: COMPARATOR
Intervention: Control (non-obese subjects)
Number of subjects: 18
Study 8418273 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunodetection (RAID) with 123I-labeled fragments, F(ab')2 and Fab' of IMMU-4, an anti-CEA monoclonal antibody
Number of subjects: 62
Study 8418273 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunodetection (RAID)
Number of subjects: 62
Study 8418273 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 62
Study 3763079 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mL Plasma‐Lyte A
Number of subjects: 45
Study 3763079 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mL 5% albumin (colloid infusion)
Number of subjects: 45
Study 3763079 — intervention group
Group type: COMPARATOR
Intervention: 1000 mL Plasma‐Lyte A
Number of subjects: 45
Study 30869814 — intervention group
Group type: EXPERIMENTAL
Intervention: BLI-bright
Number of subjects: 10
Study 30869814 — intervention group
Group type: EXPERIMENTAL
Intervention: LCI
Number of subjects: 10
Study 30869814 — intervention group
Group type: COMPARATOR
Intervention: WLI
Number of subjects: 10
Study 30179153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (combined aspirin, clopidogrel and dipyridamole)
Number of subjects: 3096
Study 30179153 — intervention group
Group type: COMPARATOR
Intervention: Guideline therapy (combined aspirin and dipyridamole, or clopidogrel alone)
Number of subjects: 3096
Study 26940692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 238
Study 26940692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 25297989 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine TDM
Number of subjects: 56
Study 25297989 — intervention group
Group type: COMPARATOR
Intervention: Rescue TDM
Number of subjects: 56
Study 25297989 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine TDM (with dosage recommendations adopted)
Number of subjects: 56
Study 25297989 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine TDM (median C min)
Number of subjects: 56
Study 25297989 — intervention group
Group type: COMPARATOR
Intervention: Rescue TDM (median C min)
Number of subjects: 56
Study 22686181 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia DCLC (SA-DCLC)
Number of subjects: 180
Study 22686181 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia DCLC (GA-DCLC)
Number of subjects: 180
Study 20189160 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2-mm clear corneal incision
Number of subjects: 60
Study 20189160 — intervention group
Group type: COMPARATOR
Intervention: 2.65-mm clear corneal incision
Number of subjects: 60
Study 20189160 — intervention group
Group type: EXPERIMENTAL
Intervention: Both incision sizes
Number of subjects: 60
Study 20189160 — intervention group
Group type: EXPERIMENTAL
Intervention: Side port incision
Number of subjects: 60
Study 18222450 — intervention group
Group type: EXPERIMENTAL
Intervention: isosorbide mononitrate (IMN)
Number of subjects: 102
Study 18222450 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 102
Study 15641953 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 60
Study 15641953 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 12860493 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 0.25, 0.5, 1, 3, or 5 mg/kg i.v.
Number of subjects: 60
Study 12860493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12860493 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 60
Study 10527826 — intervention group
Group type: EXPERIMENTAL
Intervention: uPA
Number of subjects: 0
Study 10527826 — intervention group
Group type: EXPERIMENTAL
Intervention: uPAR
Number of subjects: 0
Study 8664717 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurse visits over 12 months, minimum of six visits during the first six months.
Number of subjects: 240
Study 8664717 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurse visits for mildly disabled patients (Barthel index 15-19).
Number of subjects: 240
Study 8664717 — intervention group
Group type: COMPARATOR
Intervention: Control group received no visits.
Number of subjects: 240
Study 2051352 — intervention group
Group type: EXPERIMENTAL
Intervention: Threaded dowels (nine types)
Number of subjects: 140
Study 2051352 — intervention group
Group type: COMPARATOR
Intervention: Nonthreaded dowels (three types)
Number of subjects: 140
Study 6839972 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular sequential pacemaker (group B)
Number of subjects: 16
Study 6839972 — intervention group
Group type: COMPARATOR
Intervention: Ventricular stimulating pacemaker (group A)
Number of subjects: 16
Study 30566758 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab 9 mg
Number of subjects: 30
Study 30566758 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab 18 mg
Number of subjects: 30
Study 30566758 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab 27 mg
Number of subjects: 30
Study 30566758 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study 26035669 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity, home-based exercise protocol led by an advanced practice nurse for 12 weeks (14-type joint exercises and walking)
Number of subjects: 77
Study 26035669 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 77
Study 24960402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2‐6 (Arm A)
Number of subjects: 30
Study 24960402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab 840 mg q3w for six cycles (Arm B)
Number of subjects: 30
Study 22858630 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (3 × 45 min on a bicycle ergometer at 50% of their altitude‐specific maximal workload)
Number of subjects: 16
Study 22858630 — intervention group
Group type: COMPARATOR
Intervention: Rest (no exercise)
Number of subjects: 16
Study 22858630 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 16
Study 19324501 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 142
Study 19324501 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize-based Contingency Management (prize CM)
Number of subjects: 142
Study 19324501 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher-based Contingency Management (voucher CM)
Number of subjects: 142
Study 17077105 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN‐DBS) ON
Number of subjects: 11
Study 17077105 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN‐DBS) OFF
Number of subjects: 11
Study 15701213 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine syrup 1.25 mg (0.5 mg/mL) once daily for ages 2-5 years
Number of subjects: 231
Study 15701213 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine syrup 2.5 mg once daily for ages 6-11 years
Number of subjects: 231
Study 15701213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 11730186 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0
Study 11730186 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol plus Beclomethasone
Number of subjects: 0
Study 11730186 — intervention group
Group type: COMPARATOR
Intervention: Control (Baseline)
Number of subjects: 0
Study 9475319 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postnatal hypoglycaemia
Number of subjects: 118
Study 9475319 — intervention group
Group type: COMPARATOR
Intervention: Maternal hyperglycaemia
Number of subjects: 118
Study 9475319 — intervention group
Group type: COMPARATOR
Intervention: Cord insulin-like growth factor-I or glucagon concentrations
Number of subjects: 118
Study 7934537 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 586
Study 7934537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 2963522 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200, 400 or 600 mg once daily)
Number of subjects: 30
Study 2963522 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (12.5, 25 or 37.5 mg once daily)
Number of subjects: 30
Study 31609443 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEFLW+ (patients who developed EVLW during exercise)
Number of subjects: 61
Study 31609443 — intervention group
Group type: COMPARATOR
Intervention: HFpEFLW- (patients who did not develop EVLW during exercise)
Number of subjects: 61
Study 31609443 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEFLW+
Number of subjects: 61
Study 27733895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional risk screening
Number of subjects: 185
Study 27733895 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallow testing
Number of subjects: 185
Study 27733895 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive implementation of screening
Number of subjects: 185
Study 27733895 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of nutritional risk
Number of subjects: 185
Study 27733895 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial swallow test failure
Number of subjects: 185
Study 24617243 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation + Massage (Group A)
Number of subjects: 60
Study 24617243 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation + Acupuncture (Group B)
Number of subjects: 60
Study 21459659 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 392
Study 21459659 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 392
Study 18270224 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-LIPUS
Number of subjects: 37
Study 18270224 — intervention group
Group type: COMPARATOR
Intervention: Inactive-LIPUS (placebo)
Number of subjects: 37
Study 16549462 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 9
Study 16549462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 9
Study 16549462 — intervention group
Group type: COMPARATOR
Intervention: Control (normolipidemic patients)
Number of subjects: 9
Study 15196519 — intervention group
Group type: EXPERIMENTAL
Intervention: Light touch (L)
Number of subjects: 20
Study 15196519 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy touch (H)
Number of subjects: 20
Study 15196519 — intervention group
Group type: COMPARATOR
Intervention: No touch (N)
Number of subjects: 20
Study 11743267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (3 microg./kg. per minute infusion)
Number of subjects: 24
Study 11743267 — intervention group
Group type: COMPARATOR
Intervention: No dopamine (control group)
Number of subjects: 24
Study 9718103 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment and 12-step groups
Number of subjects: 3018
Study 9718103 — intervention group
Group type: COMPARATOR
Intervention: No aftercare
Number of subjects: 3018
Study 9718103 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient mental health treatment and 12-step group attendance
Number of subjects: 3018
Study 9718103 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular outpatient appointments
Number of subjects: 3018
Study 7655203 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical therapy with prednisolone 1% eye drops (Inflanefran forte) 5 times per day
Number of subjects: 30
Study 7655203 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival injection of 4 mg dexamethasone (Fortecortin) immediately at the end of surgery; topical therapy as in group A
Number of subjects: 30
Study 2528941 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 47
Study 2528941 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 47
Study 5801346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal fluid infusion with normal saline and 28 mEq of potassium chloride per litre
Number of subjects: 91
Study 5801346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal fluid infusion with half-strength Darrow's solution
Number of subjects: 91
Study 5801346 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with promazine
Number of subjects: 91
Study 31738680 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon skin pad
Number of subjects: 32
Study 31738680 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea towel
Number of subjects: 32
Study 31738680 — intervention group
Group type: COMPARATOR
Intervention: Video
Number of subjects: 32
Study 30499374 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio diary method
Number of subjects: 0
Study 28657396 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous methylprednisolone 125 mg (group MP)
Number of subjects: 61
Study 28657396 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline IV (group C)
Number of subjects: 61
Study 25386830 — intervention group
Group type: EXPERIMENTAL
Intervention: Capoeira and jumping exercise intervention (10-min, 3 times per week for 9 months)
Number of subjects: 188
Study 23940225 — intervention group
Group type: EXPERIMENTAL
Intervention: DD AC→PG (DD doxorubicin and cyclophosphamide followed by DD paclitaxel with gemcitabine)
Number of subjects: 4894
Study 23940225 — intervention group
Group type: COMPARATOR
Intervention: DD AC→P (DD doxorubicin and cyclophosphamide followed by DD paclitaxel)
Number of subjects: 4894
Study 23940225 — intervention group
Group type: EXPERIMENTAL
Intervention: DD AC→PG
Number of subjects: 4894
Study 23940225 — intervention group
Group type: COMPARATOR
Intervention: DD AC→P
Number of subjects: 4894
Study 23940225 — intervention group
Group type: COMPARATOR
Intervention: TAC (docetaxel, doxorubicin, and cyclophosphamide)
Number of subjects: 4894
Study 23940225 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC
Number of subjects: 4894
Study 21555324 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiVol fluid status monitoring with CareAlert notification
Number of subjects: 1000
Study 21555324 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical assessment (regular care)
Number of subjects: 1000
Study 19421839 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating electrodes
Number of subjects: 42
Study 19421839 — intervention group
Group type: COMPARATOR
Intervention: Fixed electrodes
Number of subjects: 42
Study 16453248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of Jarsin (extract of St John's wort)
Number of subjects: 20
Study 16453248 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of Jarsin (extract of St John's wort)
Number of subjects: 20
Study 15278047 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg per day for 7 days
Number of subjects: 69
Study 15278047 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg per day for 28 days
Number of subjects: 69
Study 11802492 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Therapy Enactment Rating Scale (FTERS)
Number of subjects: 27
Study 11802492 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised FTERS
Number of subjects: 27
Study 9413749 — intervention group
Group type: COMPARATOR
Intervention: Ergometry
Number of subjects: 0
Study 9413749 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise at 60% of maximal work intensity
Number of subjects: 0
Study 8449588 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin therapy (800 mg on day 1, then 400 mg on days 2, 3, 5, 12, and 19)
Number of subjects: 40
Study 8449588 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin therapy (800 mg initially, then 400 mg at weekly intervals)
Number of subjects: 40
Study 8449588 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin therapy
Number of subjects: 40
Study 3300316 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice daily
Number of subjects: 392
Study 3300316 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg three times a day
Number of subjects: 392
Study 3300316 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (160 mg/800 mg) twice daily
Number of subjects: 392
Study 3300316 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (both doses)
Number of subjects: 392
Study 3300316 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 392
Study 3300316 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (lower dose)
Number of subjects: 392
Study 3300316 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (higher dose)
Number of subjects: 392